Medovex Corp Stock Z Score
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Medovex |
Medovex Corp OTC Stock Z Score Analysis
Medovex Corp's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionAccording to the company's disclosures, Medovex Corp has a Z Score of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The z score for all United States stocks is 100.0% higher than that of the company.
Medovex Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medovex Corp's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Medovex Corp could also be used in its relative valuation, which is a method of valuing Medovex Corp by comparing valuation metrics of similar companies.Medovex Corp is currently under evaluation in z score category among its peers.
Medovex Fundamentals
Return On Equity | -4.6 | |||
Return On Asset | -3.48 | |||
Operating Margin | (3.51) % | |||
Current Valuation | 8.88 M | |||
Shares Outstanding | 477.61 K | |||
Shares Owned By Insiders | 25.51 % | |||
Number Of Shares Shorted | 294 | |||
Price To Earning | (1.53) X | |||
Price To Book | 34.90 X | |||
Price To Sales | 3.68 X | |||
Revenue | 1.61 M | |||
Gross Profit | 906.81 K | |||
EBITDA | (4.61 M) | |||
Net Income | (4.8 M) | |||
Cash And Equivalents | 45.88 K | |||
Cash Per Share | 0.16 X | |||
Total Debt | 3.88 M | |||
Debt To Equity | 2.61 % | |||
Current Ratio | 0.04 X | |||
Book Value Per Share | (17.98) X | |||
Cash Flow From Operations | (4.81 M) | |||
Short Ratio | 3.47 X | |||
Earnings Per Share | (0.05) X | |||
Target Price | 1.75 | |||
Beta | 0.73 | |||
Market Capitalization | 1.06 M | |||
Total Asset | 321.4 K | |||
Retained Earnings | (38.35 M) | |||
Working Capital | 3.33 M | |||
Current Asset | 4.18 M | |||
Current Liabilities | 851.22 K | |||
Net Asset | 321.4 K |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Medovex OTC Stock
If you are still planning to invest in Medovex Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medovex Corp's history and understand the potential risks before investing.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |